WHERE ARE YOU?

Concept Pre-Sub Submission prep Newly cleared Raising Postmarket & security

THE TAPE

Elucid raises $55M Series D with FFR-CT 510(k) under FDA review Enovis to buy eCential Robotics for 155 million euros FDA authorizes Vitestro's Aletta, the first autonomous blood-drawing robot, five months after a $70M Series B Renata Medical raises $25M Series D to scale the Minima pediatric stent FDA opens a docket on how to regulate generative AI devices FDA clears Jupiter Endovascular's Vertex thrombectomy system for pulmonary embolism in 89 days FDA clears Wandercraft's Eve, the first self-balancing exoskeleton for home use Meduloc raises $4M Series B to start alpha launch of its nitinol fracture implant FDA sets FY2027 device user fees: $28,653 for a 510(k), $13,785 to register Elucid raises $55M Series D with FFR-CT 510(k) under FDA review Enovis to buy eCential Robotics for 155 million euros FDA authorizes Vitestro's Aletta, the first autonomous blood-drawing robot, five months after a $70M Series B Renata Medical raises $25M Series D to scale the Minima pediatric stent FDA opens a docket on how to regulate generative AI devices FDA clears Jupiter Endovascular's Vertex thrombectomy system for pulmonary embolism in 89 days FDA clears Wandercraft's Eve, the first self-balancing exoskeleton for home use Meduloc raises $4M Series B to start alpha launch of its nitinol fracture implant FDA sets FY2027 device user fees: $28,653 for a 510(k), $13,785 to register

Series B

Meduloc raises $4M Series B to start alpha launch of its nitinol fracture implant

MedDevice Startups Staff · Aug 6 · 1 min read · Via Ortho Spine News

Meduloc closed a $4M Series B on August 6, 2026. GenHenn Capital led. Life Sciences Greenhouse Investments, Ben Franklin Technology Partners of Southeastern Pennsylvania, Broad Street Angels and former Dodgers player Andre Ethier also invested.

The Meduloc Intramedullary Fracture Fixation System is a flexible nitinol implant placed inside the bone canal. It is a sterile, single-use system for upper and lower extremity long-bone fractures in adults and children. FDA cleared it under K250316 on October 29, 2025, a traditional 510(k) with product code JDW. President and CEO Sarah Sachinis said the money funds a controlled alpha launch beginning in early August, clinical evidence and commercial infrastructure. Four million dollars is a small Series B for orthopedics. A controlled alpha launch is the right-sized use for it.

Questions & Answers

How much did Meduloc raise in its Series B?

Meduloc closed a $4M Series B on August 6, 2026, led by GenHenn Capital, to fund a controlled alpha launch of its nitinol fracture fixation implant.

What did FDA clear under K250316?

K250316 is the traditional 510(k) for the Meduloc Intramedullary Fracture Fixation System, a flexible nitinol implant for long-bone fractures, cleared October 29, 2025, under product code JDW.

← Back to Fundraising